These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 27775567)

  • 21. Triptolide and its prodrug Minnelide target high-risk MYC-amplified medulloblastoma in preclinical models.
    Rodriguez-Blanco J; Salvador AD; Suter RK; Swiderska-Syn M; Palomo-Caturla I; Kliebe V; Shahani P; Peterson K; Turos-Cabal M; Vieira ME; Wynn DT; Howell AJ; Yang F; Ban Y; McCrea HJ; Zindy F; Danis E; Vibhakar R; Jermakowicz A; Martin V; Coss CC; Harris BT; de Cubas A; Chen XS; Barnoud T; Roussel MF; Ayad NG; Robbins DJ
    J Clin Invest; 2024 Jun; 134(15):. PubMed ID: 38885332
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Silencing of thrombospondin-1 is critical for myc-induced metastatic phenotypes in medulloblastoma.
    Zhou L; Picard D; Ra YS; Li M; Northcott PA; Hu Y; Stearns D; Hawkins C; Taylor MD; Rutka J; Der SD; Huang A
    Cancer Res; 2010 Oct; 70(20):8199-210. PubMed ID: 20876797
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modeling medulloblastoma in vivo and with human cerebellar organoids.
    Ballabio C; Anderle M; Gianesello M; Lago C; Miele E; Cardano M; Aiello G; Piazza S; Caron D; Gianno F; Ciolfi A; Pedace L; Mastronuzzi A; Tartaglia M; Locatelli F; Ferretti E; Giangaspero F; Tiberi L
    Nat Commun; 2020 Jan; 11(1):583. PubMed ID: 31996670
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A microRNA-1280/JAG2 network comprises a novel biological target in high-risk medulloblastoma.
    Wang F; Remke M; Bhat K; Wong ET; Zhou S; Ramaswamy V; Dubuc A; Fonkem E; Salem S; Zhang H; Hsieh TC; O'Rourke ST; Wu L; Li DW; Hawkins C; Kohane IS; Wu JM; Wu M; Taylor MD; Wu E
    Oncotarget; 2015 Feb; 6(5):2709-24. PubMed ID: 25576913
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dormant SOX9-Positive Cells Facilitate MYC-Driven Recurrence of Medulloblastoma.
    Borgenvik A; Holmberg KO; Bolin S; Zhao M; Savov V; Rosén G; Hutter S; Garancher A; Rahmanto AS; Bergström T; Olsen TK; Mainwaring OJ; Sattanino D; Verbaan AD; Rusert JM; Sundström A; Bravo MB; Dang Y; Wenz AS; Richardson S; Fotaki G; Hill RM; Dubuc AM; Kalushkova A; Remke M; Čančer M; Jernberg-Wiklund H; Giraud G; Chen X; Taylor MD; Sangfelt O; Clifford SC; Schüller U; Wechsler-Reya RJ; Weishaupt H; Swartling FJ
    Cancer Res; 2022 Dec; 82(24):4586-4603. PubMed ID: 36219398
    [TBL] [Abstract][Full Text] [Related]  

  • 26. C-MYC expression in medulloblastoma and its prognostic value.
    Herms J; Neidt I; Lüscher B; Sommer A; Schürmann P; Schröder T; Bergmann M; Wilken B; Probst-Cousin S; Hernáiz-Driever P; Behnke J; Hanefeld F; Pietsch T; Kretzschmar HA
    Int J Cancer; 2000 Sep; 89(5):395-402. PubMed ID: 11008200
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A mouse model of the most aggressive subgroup of human medulloblastoma.
    Kawauchi D; Robinson G; Uziel T; Gibson P; Rehg J; Gao C; Finkelstein D; Qu C; Pounds S; Ellison DW; Gilbertson RJ; Roussel MF
    Cancer Cell; 2012 Feb; 21(2):168-80. PubMed ID: 22340591
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lack of Rb and p53 delays cerebellar development and predisposes to large cell anaplastic medulloblastoma through amplification of N-Myc and Ptch2.
    Shakhova O; Leung C; van Montfort E; Berns A; Marino S
    Cancer Res; 2006 May; 66(10):5190-200. PubMed ID: 16707443
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel MYC-driven medulloblastoma models from multiple embryonic cerebellar cells.
    Kawauchi D; Ogg RJ; Liu L; Shih DJH; Finkelstein D; Murphy BL; Rehg JE; Korshunov A; Calabrese C; Zindy F; Phoenix T; Kawaguchi Y; Gronych J; Gilbertson RJ; Lichter P; Gajjar A; Kool M; Northcott PA; Pfister SM; Roussel MF
    Oncogene; 2017 Sep; 36(37):5231-5242. PubMed ID: 28504719
    [TBL] [Abstract][Full Text] [Related]  

  • 30. OLIG2 Is a Determinant for the Relapse of MYC-Amplified Medulloblastoma.
    Xu Z; Murad N; Malawsky D; Tao R; Rivero-Hinojosa S; Holdhof D; Schüller U; Zhang P; Lazarski C; Rood BR; Packer R; Gershon T; Pei Y
    Clin Cancer Res; 2022 Oct; 28(19):4278-4291. PubMed ID: 35736214
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Which clinical and biological tumor markers proved predictive in the prospective multicenter trial HIT'91--implications for investigating childhood medulloblastoma.
    Grotzer MA; von Hoff K; von Bueren AO; Shalaby T; Hartmann W; Warmuth-Metz M; Emser A; Kortmann RD; Kuehl J; Pietsch T; Rutkowski S
    Klin Padiatr; 2007; 219(6):312-7. PubMed ID: 18050040
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential forms of p53 in medulloblastoma primary tumors, cell lines and xenografts.
    Philipova T; Baryawno N; Hartmann W; Pietsch T; Druid H; Johnsen JI; Ekström TJ
    Int J Oncol; 2011 Mar; 38(3):843-9. PubMed ID: 21184030
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RNA interference screening identifies a novel role for PCTK1/CDK16 in medulloblastoma with c-Myc amplification.
    Ćwiek P; Leni Z; Salm F; Dimitrova V; Styp-Rekowska B; Chiriano G; Carroll M; Höland K; Djonov V; Scapozza L; Guiry P; Arcaro A
    Oncotarget; 2015 Jan; 6(1):116-29. PubMed ID: 25402633
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Restoration of miR-193a expression is tumor-suppressive in MYC amplified Group 3 medulloblastoma.
    Bharambe HS; Joshi A; Yogi K; Kazi S; Shirsat NV
    Acta Neuropathol Commun; 2020 May; 8(1):70. PubMed ID: 32410663
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Joint binding of OTX2 and MYC in promotor regions is associated with high gene expression in medulloblastoma.
    Bunt J; Hasselt NE; Zwijnenburg DA; Koster J; Versteeg R; Kool M
    PLoS One; 2011; 6(10):e26058. PubMed ID: 22016811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MYC Promotes Aggressive Growth and Metastasis of a WNT-Medulloblastoma Mouse Model.
    Hartley R; Phoenix TN
    Dev Neurosci; 2024; 46(3):167-178. PubMed ID: 37544301
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low-level copy number changes of MYC genes have a prognostic impact in medulloblastoma.
    Zitterbart K; Filkova H; Tomasikova L; Necesalova E; Zambo I; Kantorova D; Slamova I; Vranova V; Zezulkova D; Pesakova M; Pavelka Z; Veselska R; Kuglik P; Sterba J
    J Neurooncol; 2011 Mar; 102(1):25-33. PubMed ID: 20607354
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overexpressed TP73 induces apoptosis in medulloblastoma.
    Castellino RC; De Bortoli M; Lin LL; Skapura DG; Rajan JA; Adesina AM; Perlaky L; Irwin MS; Kim JY
    BMC Cancer; 2007 Jul; 7():127. PubMed ID: 17626635
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BarTeL, a Genetically Versatile, Bioluminescent and Granule Neuron Precursor-Targeted Mouse Model for Medulloblastoma.
    Shackleford GM; Shi XH; Swanson KS; Mahdi MY; Gonzalez-Gomez I; Asgharzadeh S; D'Apuzzo M; Erdreich-Epstein A; Moats RA
    PLoS One; 2016; 11(6):e0156907. PubMed ID: 27310018
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Risk stratification in medulloblastoma: screening for molecular markers].
    Ebinger M; Senf L; Scheurlen W
    Klin Padiatr; 2006; 218(3):139-42. PubMed ID: 16688669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.